Correction to: Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis  C and Cirrhosis
(Source: Advances in Therapy)
Source: Advances in Therapy - April 10, 2024 Category: Drugs & Pharmacology Source Type: research

Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research
ConclusionOverall, the findings from this study provide evidence for the content validity of the UWDRS Part  II and supportive evidence for the content validity of Part III. The UWDRS should be used in conjunction with additional clinical outcomes assessments, specifically those evaluating the hepatic and psychiatric signs/symptoms of WD, to provide a comprehensive evaluation of the WD patient experienc e. (Source: Advances in Therapy)
Source: Advances in Therapy - April 4, 2024 Category: Drugs & Pharmacology Source Type: research

Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48  Weeks: 307 Open-Label Extension Study
ConclusionPegcetacoplan sustained long-term improvements in hemoglobin concentrations, fatigue reduction, and transfusion burden. Long-term safety findings corroborate the favorable profile established for pegcetacoplan.Trial RegistrationClinicalTrials.gov identifier, NCT03531255. (Source: Advances in Therapy)
Source: Advances in Therapy - April 4, 2024 Category: Drugs & Pharmacology Source Type: research

Perceptions and Experiences of People with Obesity and Type 2 Diabetes Around Appetite and Eating Behaviors: A Qualitative Study
ConclusionThe findings build upon existing models of factors influencing food choices. Findings confirm prior research regarding impact of drivers/triggers on food choice in people with obesity and T2D and indicate underlying disease state does not appear to influence eating behaviors in people with stable body weight. (Source: Advances in Therapy)
Source: Advances in Therapy - April 1, 2024 Category: Drugs & Pharmacology Source Type: research

Evolving Role of Viltolarsen for Treatment of Duchenne Muscular Dystrophy
AbstractDuchenne muscular dystrophy (DMD) is one of the most prevalent X-linked inherited neuromuscular disorders, with an estimated incidence between 1 in 3500 and 5000 live male births. The median life expectancy at birth is around 30  years due to a rapid and severe disease progression. Currently, there is no cure for DMD, and the standard of care is mainly palliative therapy and glucocorticoids to mitigate symptoms and improve quality of life. Recent advances in phosphorodiamidate morpholino antisense oligonucleotide (PMO) tec hnology has proven optimistic in providing a disease-modifying therapy rather than a palliat...
Source: Advances in Therapy - March 24, 2024 Category: Drugs & Pharmacology Source Type: research

Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives
The objective of this article is to describe the perspectives of five caregivers of girls in trofinetide clinical trials as well as those of three nurse trial coordinators, with a focus on management of GI symptoms of trofinetide treatment.Audio Abstract available for this article.Audio Abstract: Jane Lane provides an overview and discusses key findings of the article titled “Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives.” (MP4 83274 KB) (Source: Advances in Therapy)
Source: Advances in Therapy - March 24, 2024 Category: Drugs & Pharmacology Source Type: research

Selective Internal Radiation Therapy Using Y-90 Resin Microspheres for Metastatic Colorectal Cancer: An Updated Systematic Review and Network Meta-Analysis
ConclusionCurrent evidence supports SIRT treatment in patients with chemotherapy-refractory or chemotherapy-intolerant mCRC compared to newer oral agents, with comparable OS and low incidence of AEs. (Source: Advances in Therapy)
Source: Advances in Therapy - March 24, 2024 Category: Drugs & Pharmacology Source Type: research

Correction to: Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia
(Source: Advances in Therapy)
Source: Advances in Therapy - March 24, 2024 Category: Drugs & Pharmacology Source Type: research

Correction to: Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients ’ Real-World Insights for Optimizing Outcomes
(Source: Advances in Therapy)
Source: Advances in Therapy - March 24, 2024 Category: Drugs & Pharmacology Source Type: research

‘Totality of Evidence’ Approach in the Development of GP2017, an Approved Adalimumab Biosimilar
ConclusionOverall, the Totality of Evidence provided for biosimilar adalimumab, SDZ-ADL, confirmed the analytical, functional and clinical similarity of SDZ-ADL to REF-ADL, supporting its regulatory approval and providing a data bridge with which to evaluate and support the approval of citrate-free HCF SDZ-ADL for clinical use. (Source: Advances in Therapy)
Source: Advances in Therapy - March 21, 2024 Category: Drugs & Pharmacology Source Type: research

Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300  Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study
ConclusionsThis study showed that initiation of insulin therapy with Gla-300 in people with T2DM using an individualized approach is more effective in achieving an HbA1c target. Moreover, earlier initiation of insulin therapy in people with suboptimally controlled T2DM may increase the success rate of glycemic control.A graphical abstract is available with this article.Graphical Abstract (Source: Advances in Therapy)
Source: Advances in Therapy - March 21, 2024 Category: Drugs & Pharmacology Source Type: research

Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review
ConclusionsAlthough targeted therapies demonstrate systemic benefits for patients with NSCLC, BrMs, and AGAs, there remains a continued need for effective therapies to treat and prevent BrMs in this population. Increased BBB permeability of emerging therapies may improve outcomes for this population. (Source: Advances in Therapy)
Source: Advances in Therapy - March 21, 2024 Category: Drugs & Pharmacology Source Type: research

Enhancing Drug Management, Cost Savings, and Staff Satisfaction in Anesthesiology: A Quality Improvement Project in a Chinese Tertiary Hospital
ConclusionThe quality improvement project has yielded remarkable positive outcomes, serving as a model worthy of reference and replication in similar healthcare settings. (Source: Advances in Therapy)
Source: Advances in Therapy - March 18, 2024 Category: Drugs & Pharmacology Source Type: research

Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data
ConclusionThis anchored ITC demonstrated a greater PFS benefit for D-Rd versus VRd in TIE patients with NDMM. In the absence of head-to-head trials comparing D-Rd and VRd, the present trial may help inform treatment selection in this patient population. (Source: Advances in Therapy)
Source: Advances in Therapy - March 18, 2024 Category: Drugs & Pharmacology Source Type: research

Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase  Inhibitor
ConclusionsFindings suggest that brexu-cel may offer clinically and statistically significant benefits regarding objective response, complete response, and progression-free survival compared to pirtobrutinib among patients with R/R MCL after prior cBTKi therapy. Given the short follow-up and high degree of censoring in BRUIN, an analysis incorporating updated BRUIN data may provide more definitive overall survival results. (Source: Advances in Therapy)
Source: Advances in Therapy - March 18, 2024 Category: Drugs & Pharmacology Source Type: research